NewsTradingSentimentCalendarCommunityBriefing
Stocks

Snowflake Estimates Rise 17% as Analysts Lift Q1 Outlook

By Stocks Desk · 2026-09-18 · 2 min read
A stylized snowflake crystal resting on a smooth, reflective surface
Illustration: Tradingbird

Snowflake's consensus earnings estimates have climbed significantly over the past month, driven by a wave of upward revisions from covering analysts. This shift in sentiment has already contributed to a 5.3% increase in the stock price over the last four weeks.

Snowflake Inc. (SNOW) has seen its forward earnings projections rise sharply as analysts adjust their models based on the company's recent performance. According to data reported by GN markets/earnings (en-US), the consensus estimate for the current quarter now stands at $0.60 per share, marking a 71.4% year-over-year increase. This substantial growth in expected profitability has prompted a broad reassessment of the company's near-term trajectory among market participants.

The revision trend has been heavily skewed toward the positive. Over the last 30 days, the consensus estimate for Snowflake increased by 17.53%. This aggregate change resulted from nine individual analysts raising their forecasts while only one lowered theirs. Such a lopsided distribution of updates indicates a strong alignment in expectations regarding the company's ability to deliver higher earnings than previously anticipated.

Full-Year Projections Show Strong Momentum

The optimism extends beyond the immediate quarter to the full fiscal year. The consensus estimate for annual earnings per share is currently set at $2.19, representing a 75.2% year-over-year jump. Similar to the quarterly trend, the full-year revisions have been predominantly upward. In the past month, 11 analysts increased their estimates compared to just one who decreased theirs, pushing the overall consensus higher by 13.52%.

These adjustments reflect a deeper confidence in Snowflake's operational execution and revenue generation capabilities. The consistent upward movement in both quarterly and annual figures suggests that the initial market skepticism regarding the company's growth pace is fading. Instead, the focus is shifting toward validating the higher baseline for earnings, which supports the current valuation multiples.

Rating System Reflects Positive Sentiment

Based on these estimate revisions, Snowflake currently holds a Zacks Rank #2, which is classified as a Buy. This rating system tracks the momentum of earnings estimate changes to identify potential stock movers. The shift to this category underscores the significant positive divergence between recent analyst actions and previous consensus levels. The stock's 5.3% gain over the past four weeks aligns with this improved ranking, indicating that the market is beginning to price in the higher expectations.

The correlation between rising estimates and stock price movement has been a consistent pattern for Snowflake. As the consensus EPS figures continue to be revised upward, the gap between the current stock price and the implied value of these earnings may narrow. This dynamic suggests that the recent price appreciation is grounded in fundamental data rather than speculative sentiment alone, providing a clearer basis for further potential gains.

Based on reporting by Yahoo Finance, compiled by the Tradingbird desk.

More from the Stocks desk

All desk stories
  • A digital coin resting on a smooth, reflective glass surface
    Illustration: Tradingbird

    SEC Tokenization Rule Lifts Robinhood and Coinbase

    A new SEC framework for tokenized equities drove significant intraday gains for major crypto platforms, reversing recent regulatory headwinds.

    2026-09-18
  • A close-up view of a silicon wafer featuring a precise grid of square microchips.
    Illustration: Tradingbird

    NXP COO Executes Pre-Planned Sale of 1,000 Shares

    NXP Semiconductors' COO executed a pre-planned sale of 1,000 shares, a routine move under a 10b5-1 plan despite the stock lagging broader market indices. Recent filings highlight the company's robust financial health, including 19% Q2 revenue growth and optimistic Q3 guidance, which helps contextualize the insider transaction against strong operational results.

    2026-09-18
  • A glass vial containing a clear liquid standing on a white laboratory bench
    Illustration: Tradingbird

    MapLight Therapeutics Faces 21-Month Cash Runway Amid Rising Burn

    MapLight Therapeutics holds US$305m in cash with no debt, but a 73% increase in annual burn reduces its runway to 21 months, raising potential dilution risks.

    2026-09-18